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Abstract Peroxynitrite formed in vivo from superoxide and
nitric oxide can mediate oxidation, nitration, or nitrosation
reactions, leading to impaired function, toxicity, and alterations
in signaling pathways. Protection against peroxynitrite is
important for defense of normal tissue, especially during
inflammation. Biological protection against peroxynitrite is
organized in three categories : prevention, interception, and
repair. Prevention is the control of the formation of peroxynitrite
precursors, nitric oxide and superoxide. Interception is by direct
reaction with peroxynitrite, leading to non-toxic products. In this
regard, organoselenium compounds, metalloporphyrin deriva-
tives, and peroxidases (e.g. glutathione peroxidase and myelo-
peroxidase) exhibit high second-order rate constants with
peroxynitrite. Ebselen, like glutathione peroxidase, protects in
a catalytic fashion utilizing glutathione as reductant in the
peroxynitrite reductase reaction. Protection by metalloporphyr-
ins can be maintained through glutathione or ascorbate. Repair
processes remove damaged products and restitute intact biomol-
ecules.
z 1999 Federation of European Biochemical Societies.
Key words: Peroxynitrite; Oxidation; Nitration; Protection;
Selenium; Glutathione peroxidase
1. Peroxynitrite, an oxidizing and nitrating/nitrosating agent
Peroxynitrite1 is produced by the di¡usion-limited reaction
of nitric oxide and superoxide anion. Peroxynitrite is stable,
but upon protonation to peroxynitrous acid (pKa 6.8), it de-
cays to nitrate with a rate constant of 1.3 s31 at 25‡C. Per-
oxynitrous acid is highly reactive, yielding oxidizing and ni-
trating species (see [1^5]). Oxidation reactions of peroxynitrite
include DNA damage, leading to base modi¢cation (Fig. 1) [6]
and mutation as well as single- and double-strand breaks [7,8].
Peroxynitrite also causes one- or two-electron oxidations of
sulfhydryls [9], leading to thiyl radical formation, radical
chain reactions, and depletion of thiol pools. Peroxynitrite
can also induce lipid peroxidation [10] and may play a critical
role in atherosclerosis [11]. Other oxidations include hydrox-
ylation of phenols [12]. Nitration reactions are predominantly
nitration of phenols, such as nitration of tyrosine residues in
proteins (Fig. 1). Protein tyrosine nitration by peroxynitrite
may interfere with phosphorylation/dephosphorylation signal-
ing pathways [13,14] or alter protein function. Peroxynitrite
can also cause nitrosation reactions (Fig. 1) [15,16].
At the level of the whole organism, the reactive chemistry of
peroxynitrite can be considered bene¢cial, because of its cy-
totoxicity to bacteria [17] or other invading organisms. In-
£ammatory cells, such as macrophages and neutrophils, pro-
duce large amounts of both nitric oxide and superoxide, which
in turn rapidly form peroxynitrite [18^20]. However, excessive
production of peroxynitrite can damage normal tissue. In-
deed, the formation of protein 3-nitrotyrosine in vivo has
been shown in a number of in£ammatory conditions in hu-
mans and experimental animals [21]. The physiological and
pharmacological strategies for protection against peroxynitrite
are organized in three categories : prevention, interception, and
repair (see [22]).
2. Prevention
Table 1 lists some possibilities for the prevention of the
formation of peroxynitrite. During in£ammation, the expres-
sion of inducible nitric oxide synthase (NOS II) is often up-
regulated, concomitant with an increase in NOS activity. Spe-
ci¢c inhibition of nitric oxide synthase can block generation of
nitric oxide (see Table 1). In addition to exogenous scavengers
of nitric oxide (see Table 1), hemoglobin is a good scavenger
of nitric oxide and plays a role in decreasing nitric oxide levels
in blood. Inhibitors of xanthine oxidase or of NADPH oxi-
dase decrease superoxide production. Superoxide dismutase
and mimics (e.g. metalloporphyrins; Fig. 2) can decrease
superoxide levels and thereby decrease peroxynitrite forma-
tion. Lastly, anti-in£ammatory agents, such as glucocorti-
coids, block excessive nitric oxide and superoxide formation
by counteracting the in£ammatory response.
3. Interception
A number of compounds have been shown in vitro to react
with peroxynitrite and were suggested to be useful protectants
in vivo. For determining the detoxifying capacity of the reac-
tion of a given compound with peroxynitrite, it is useful to
consider the rate constant of this reaction and the achievable
concentrations, as well as the ability of this reaction to be
catalytically maintained. For homogeneous systems, multipli-
cation of the concentration of a given compound with the
corresponding second-order rate constant for the reaction
with peroxynitrite yields the rate of disappearance of peroxy-
nitrite. This ¢rst-approximation approach was used previously
considering the reaction of peroxynitrite with CO2, hemoglo-
bin, and peroxidases [23,24]. Table 2 lists the apparent second-
order rate constants of the reaction of peroxynitrite with some
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1 The term peroxynitrite is used sometimes to refer to both the
peroxynitrite anion proper (ONOO3) and peroxynitrous acid
(ONOOH); the IUPAC names are oxoperoxonitrate(13) and hydro-
gen oxoperoxonitrate, respectively. The systematic names of nitric
oxide (NOc) and nitrosoperoxycarbonate (ONO2CO32 ) are nitrogen
monoxide and 1-carboxylato-2-nitrosodioxidane, respectively.
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endogenous compounds, their concentrations in vivo, and the
expected rate of disappearance of peroxynitrite. The rate con-
stants for some exogenous compounds are also listed.
3.1. Low-molecular-weight compounds
3.1.1. Carbon dioxide. When one considers the concentra-
tion of carbon dioxide in vivo (V1 mM) and the rate con-
stant of its reaction with peroxynitrite [25,26], the formation
of the adduct, nitrosoperoxycarbonate (ONO2CO32 ), is most
likely a major route of peroxynitrite reactivity in vivo. How-
ever, whether the carbon dioxide/peroxynitrite reaction is a
detoxication pathway in vivo is unclear [23]. For example,
carbon dioxide enhances protein tyrosine nitration by peroxy-
nitrite [27]. Further, while carbon dioxide decreases two-elec-
tron oxidation of thiols by peroxynitrite [26], one-electron
oxidation reactions are enhanced [28]. The latter pathway
would lead to thiyl radical formation and subsequent radical
chain reactions. Thus, it may be appropriate to call carbon
dioxide a modi¢er of peroxynitrite reactions rather than a
detoxi¢er.
3.1.2. Ebselen and organoselenium compounds. Selenium-
containing amino acids and the organoselenium compound
ebselen (Fig. 2) rapidly react with peroxynitrite [29^31] and
protect against DNA damage caused by peroxynitrite more
e¡ectively than their sulfur analogs [32]. The reaction scheme
depicted in Fig. 3 applies generally to ebselen or to selenocys-
teine in free or protein-bound form, such as in glutathione
peroxidase (see below). Peroxynitrite is reduced by these com-
pounds to nitrite ; the resulting selenoxide is subsequently re-
duced by GSH, establishing a catalytic cycle so that the de-
fense can be maintained in a peroxynitrite reductase reaction.
Organotellurium compounds also protect against oxidation
and nitration reactions caused by peroxynitrite [33,34];
bis[4-aminophenyl] telluride (Fig. 2) protects against peroxy-
nitrite-mediated oxidation of dihydrorhodamine 123 more ef-
¢ciently than its selenium analogue or ebselen [33].
Clinically, ebselen has been found to be protective in pa-
tients with delayed neurological de¢cits and aneurysmal sub-
arachnoid hemorrhage [35], in acute ischemic stroke [36], and
in acute middle cerebral artery occlusion [37]. Since increased
nitrotyrosine levels were found to be associated with such
neurological disorders, these protective e¡ects of ebselen could
be due in part to peroxynitrite defense.
3.1.3. Metalloporphyrins. In addition to mimicking super-
oxide dismutase, synthetic metalloporphyrins have been
shown to react with peroxynitrite at second-order rate con-
stants similar to that of ebselen [38,39] (Table 2). The metal in
the porphyrin shown in Fig. 2 can be manganese(III) or iron-
(III). Both compounds catalyze the isomerization of peroxy-
nitrite to nitrate. It is proposed that peroxynitrite attacks the
metal, and the manganese(IV) can be rereduced by thiols or
ascorbate [39,40], while the iron(IV) compound catalyzes its
own reduction [38,41]. Synthetic porphyrins have been shown
to be cytoprotective against peroxynitrite in vitro [42] and to
alleviate some of the toxic e¡ects of endotoxic shock in rats
[41,43]. It should be mentioned that nitrogen dioxide can be
released during the reaction process [39,41] and that these
compounds may enhance nitration reactions of peroxynitrite
[44].
3.1.4. Thiols and ascorbate. The interaction of peroxyni-
trite with free thiols in proteins or in glutathione is also rapid
enough, in view of their in vivo concentrations, to make this
reaction signi¢cant [2]. While the bulk of the reaction is a two-
electron reduction of peroxynitrite to nitrite, at least a portion
of peroxynitrite is reduced via a one-electron pathway, leading
to a sulfur-centered radical [9]. Ascorbate has a low second-
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Fig. 1. Examples of products formed by oxidizing and nitrating/
nitrosating reactions of peroxynitrite.
Table 1
Prevention of pathways leading to peroxynitrite formation
Compound Example Protective e¡ect
Inhibitors of nitric oxide synthases NG-Monomethyl-L-arginine
(L-NAME)
Protects against myocardial reoxygenation injury in
piglets [65]
Inhibitors of superoxide production
from xanthine oxidase or NADPH oxidase
Allopurinol Partially restores acetylcholine-elicited vasorelaxation in
isolated aortic rings from cholesterol-fed rabbits [66]
Inactivators of nitric oxide 2-Phenyl-4,4,5,5-tetramethylimid-
azoline-1-oxyl-3-oxide (carboxy-PTIO)
Delays onset and severity of experimental allergic
encephalomyelitis in mice [67]
Inactivators of superoxide Superoxide dismutase Partially restores acetylcholine-elicited vasorelaxation in
isolated femoral rings from cholesterol-fed rabbits [68]
Anti-in£ammatory agents Budesonide (glucocorticoid) Decreased protein nitrotyrosine formation and increased
breathing performance in asthmatic patients [69]
G.E. Arteel et al./FEBS Letters 445 (1999) 226^230 227
order rate constant for the reaction with peroxynitrite [45],
and even with millimolar concentrations in cells, it is unlikely
that ascorbate plays a signi¢cant role in direct reactions with
peroxynitrite (Table 2); however, in the reduction of the oxi-
dized metalloporphyrin compounds, it becomes important in
peroxynitrite defense [39,40].
3.2. Proteins
3.2.1. Myeloperoxidase and horseradish peroxidase. The
mammalian heme peroxidases (e.g. myeloperoxidase) also re-
act with peroxynitrite (Table 2) [46]. Although the concentra-
tion of myeloperoxidase in blood is low relative to more abun-
dant biomolecules that react with peroxynitrite (e.g. CO2) [24],
concentrations are much higher in in£ammatory cells (e.g.
neutrophils). Further, localized extracellular concentrations
near in£ammatory cells during respiratory bursts may be
high enough to react with peroxynitrite. In plants, the reaction
between horseradish peroxidase and peroxynitrite may also be
signi¢cant; the rate constant is 3.2U106 M31 s31 at pH 6.8,
25‡C [46]. The reaction of horseradish peroxidase can be cat-
alytically maintained using chlorogenic acid as a reductant
[47]. However, both myeloperoxidase and horseradish peroxi-
dase increase formation of nitrotyrosine by peroxynitrite [48].
3.2.2. Hemoglobin. In addition to reacting with nitric ox-
ide, hemoglobin reacts rapidly with peroxynitrite and is suit-
able for e⁄cient protection of erythrocytes. However, hemo-
globin is not able to fully protect the plasma membrane
of erythrocytes; when peroxynitrite was generated out-
side the cells, hemolysis was found to occur [49]. Oxyhemo-
globin reacts with nitric oxide to methemoglobin and
nitrate via a short-lived intermediate peroxynitrite complex
[50].
3.2.3. Glutathione peroxidase and selenoproteins. The sele-
nocysteine-containing glutathione peroxidase (GPx) can act as
a peroxynitrite reductase, preventing both oxidation and ni-
tration reactions caused by peroxynitrite [51]. GPx inactivates
peroxynitrite in a catalytic reaction at the stoichiometry
known for that of hydroperoxide reduction, i.e. the classical
GPx reaction (Fig. 3), similar to that described above for
ebselen, and also for selenomethionine. Increases in nitrite
during exposure to peroxynitrite were observed with GPx
[51], indicating two-electron reduction of peroxynitrite ; how-
ever, the nitrite yield was less than complete (V50%). The
second-order rate constant for the reaction of glutathione
peroxidase (tetrameric) with peroxynitrite is 8.0U106 M31
s31 (Table 2) [52]. Further, there is no net loss of GPx activity
when GPx is maintained in the reduced state by supplying
reductants [51,52]. These data suggest that inside the cell,
GPx outcompetes thiols for the reaction with peroxynitrite
and can compete with carbon dioxide (Table 2). Thus, the
reaction of GPx with peroxynitrite is considered a biologically
e⁄cient detoxication pathway in vivo.
Selenoprotein P in human plasma also protects against per-
oxynitrite [53], suggesting that it may serve as a protectant
against peroxynitrite in human blood. The heparin binding
domains of selenoprotein P enable surface coating of cellular
membranes (e.g. endothelial cells) [54,55]; this may serve as a
protective barrier against peroxynitrite. Furthermore, the se-
lenoprotein thioredoxin reductase can function in the reduc-
tion of peroxynitrite by selenocysteine or ebselen [55a].
Selenomethionine is oxidized to the selenoxide by peroxyni-
trite with a second-order rate constant approximately 100-fold
higher than for the reaction of methionine with peroxynitrite
[56]. Methionine selenoxide is e¡ectively and rapidly reduced
to selenomethionine by glutathione, permitting a catalytic re-
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Fig. 2. Structures of some low-molecular-weight compounds with
high second-order rate constants for the reaction with peroxynitrite,
including organoselenium, organotellurium, and synthetic metal por-
phyrin compounds (see Table 2).
Fig. 3. Proposed catalytic mechanism of selenoperoxidases in the re-
duction of peroxynitrite to nitrite (or peroxynitrous acid to nitrous
acid). The mechanism is based on that established for glutathione
peroxidases and the mimic, ebselen, which use ROOH and ROH as
substrate and product, respectively (see [29,51]). Selenomethionine
can also react with peroxynitrite, with the resultant methionine se-
lenoxide being reduced by glutathione in a catalytic cycle [57].
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action by selenomethionyl residues in proteins [57]. In con-
trast, methionine sulfoxide is not reduced by glutathione; the
enzyme methionine sulfoxide reductase is necessary for the
reduction of methionine sulfoxide to methionine [58]. Since
selenomethionine can occur in proteins such as hemoglobin
[59], these residues may play a defensive role against peroxy-
nitrite.
3.2.4. Albumin. The high concentration of albumin in
plasma makes its reaction with peroxynitrite signi¢cant (Table
2). The reaction of peroxynitrite with albumin is largely due to
the one free cysteine residue [60]. Further, human albumin
contains six tyrosine residues adjacent to glutamate residues,
which are preferentially nitrated by peroxynitrite [3]. Indeed,
oxidized [28] and nitrated [51,53] products of albumin are
observable when peroxynitrite is added to plasma.
4. Repair
Protection from the e¡ects of peroxynitrite can be by repair
of damage once it has occurred. As prevention and intercep-
tion processes are not completely e¡ective, damage products
could continuously form in low yields during excessive
peroxynitrite generation and may accumulate. As discussed
above, damaged biomolecules include DNA, occurring as
modi¢ed bases or in the form of single- or double-strand
breaks [8], or membranes, occurring as phospholipid oxida-
tion and nitration products, or proteins, occurring as oxidized
and nitrated amino acid side-chains. Correspondingly, there
are biological systems involved in DNA repair [8,61], modi¢ed
lipid turnover [62,63], and proteolysis [64] that are capable of
providing the functions of restitution or replenishment. The
emerging and active ¢eld of research on repair of peroxyni-
trite-induced damage is not reviewed in detail here.
5. Concluding remarks
Defense against peroxynitrite occurs at various levels ; de-
fense strategies can vary between tissues and between subcel-
lular compartments. The damaging potential of peroxynitrite
is mediated by reactive oxidizing and nitrating species formed
during the reaction of peroxynitrite with biomolecules. There-
fore, cellular strategies of antioxidant defense not speci¢c to
peroxynitrite may also play a role in defense against damage
due to peroxynitrite.
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